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Abstract 
Chemokines, including chemokine (C-X-C motif ) ligand 1 (CXCL1), regulate tumor epithelial-stromal interactions that 
facilitate tumor growth and invasion. Recently, several studies have linked CXCL1 expression to bladder cancer (BCa). 
In this study, we aimed to determine if increased levels of urinary CXCL1 were found in BCa patients. Voided urines 
from 86 subjects, cancer subjects (n = 43), non-cancer subjects (n = 43) were analyzed. The protein concentration 
of CXCL1 was assessed by enzyme-linked immunosorbent assay (ELISA). CXCL1 concentration level was normalized 
using urinary protein and urinary creatinine concentrations. We used the area under the curve of a receiver operating 
characteristic (AUROC) to investigate the performance of CXCL1 in detecting BCa. Mean urinary concentrations of 
CXCL1 were significantly higher in subjects with BCa compared to subjects without BCa (179.8 ± 371.7 pg/mg of cre-
atinine vs. 28.2 ± 71.9 pg/mg, respectively p = 0.0009). Urinary CXCL1 possessed a sensitivity of 55.81 %, specificity of 
83.72 %, positive predictive value of 77.42 %, negative predictive value of 65.46 %, and an overall accuracy of 69.77 % 
(AUROC: 0.7015, 95 % CI 0.5903–0.8126). These results indicate that CXCL1 is elevated in BCa when compared to non-
cancer subjects, but lacks robustness as a standalone urinary biomarker. Additional studies into CXCL1 may shed more 
light on the role of CXCL1 in BCa tumorigenesis as well as ramifications of therapeutically targeting CXCL1.
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Background
Chemokines are a family of small peptides that induce 
directed chemotaxis in nearby responsive cells. Their 
canonical function is immune and inflammatory reac-
tions, such as allergic disorders, autoimmune diseases, 
and in viral infections. On the other hand, overexpres-
sion and uncontrolled activity of certain chemokines 
have been implicated in the initiation and progression of 
several cancers through a variety of mechanisms. Specifi-
cally, chronic exposure of cells to a chemokine-rich envi-
ronment induces accumulation of macrophage and T cell, 
chronic activation of macrophages, abnormal angiogene-
sis, and DNA damage because of the presence of reactive 
oxygen species (Gillitzer and Goebeler 2001). In addition, 
it is known that chemokines regulate multiple processes 
associated with tumor growth and progression including 
primary tumor growth, tumor angiogenesis and devel-
opment of metastatic disease. Thus, due to these effects, 
some reports have linked chemokines to more aggressive 
cancers (Hembruff and Cheng 2009).
One chemokine of interest is chemokine (C-X-C) 
ligand 1 (CXCL1), also known as growth-regulated 
oncogene-alpha or melanoma growth stimulatory activ-
ity, alpha. Accumulating evidence suggest that CXCL1 
is overexpressed in colon, skin and breast cancers (Ver-
beke et al. 2011; Dhawan and Richmond 2002; Vazquez-
Martin et  al. 2007; Lerebours et  al. 2008). Previously, 
Kawanishi et  al. reported significantly higher urinary 
CXCL1 concentrations in patients with muscle invasive 
bladder cancer (MIBC) relative to non-muscle inva-
sive bladder cancer (NMIBC), suggesting CXCL1 as an 
independent factor for predicting the invasive pheno-
type (Kawanishi et  al. 2008). In an urine-based follow-
up study, Nakashima et  al. confirmed these results with 
measuring the concentration of urinary CXCL1 in 175 
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patients with bladder cancer (BCa) and 30 healthy vol-
unteers (Nakashima et al. 2015). Subsequently, our group 
demonstrated that CXCL1 protein expression was pre-
sent in cancerous tissues and entirely absent in benign 
tissue. Furthermore, CXCL1 immunostaining was signifi-
cantly higher in high-grade tumors and MIBC relative to 
low-grade tumors and NMIBC, respectively. Increased 
CXCL1 immunostaining was similarly associated with 
reduced disease-specific survival (Miyake et al. 2013).
Herein, we aimed to expand on the above data and 




Under Institutional Review Board approval by Western 
Institutional Review Board (Puyallup, WA) and informed 
consent (IRB #Rosser 2014-1), voided urine samples and 
associated clinical information were prospectively col-
lected. The urine samples were randomly collected from 
each subject. Urine cytology was collected at the same 
time as the urine samples. The study cohort consisted of 
43 subjects with no previous history of urothelial carci-
noma, gross hematuria, active urinary tract infection, 
or urolithiasis, and 43 subjects with newly diagnosed 
primary urothelial carcinoma. Median follow-up was 
6  months. This study, which consisted of 86 subjects, 
adhered to PRoBE (Feng et  al. 2013) and STARD crite-
ria (Bossuyt et  al. 2004). All subjects were evaluated in 
the outpatient Urology clinic. Urinalysis and urinary 
cytology were performed on all subjects. Furthermore, 
in our cancer group, axial imaging of the abdomen and 
pelvis and cystoscopy were performed, and urothelial 
carcinoma was confirmed by histological examination of 
excised tissue.
Specimen processing and analysis
Prior to any type of therapeutic intervention, 100 mL of 
voided urine was obtained from each subject. Voided 
urine sample was immediately placed into 4  °C refrig-
erator after collection. Fifty milliliters of urine was sent 
to the clinical laboratory for urinalysis and voided uri-
nary cytology (VUC). The remaining 50 mL of urine was 
assigned a unique identifying number before immediate 
delivery and laboratory processing. The urine sample was 
transported to the laboratory under refrigerated condi-
tions. Within 4 h of collection, the sample was processed 
in the laboratory. Each urine sample was centrifuged at 
600×g 4 °C for 5 min. The supernatant was decanted and 
aliquoted, and the urinary pellet was snap frozen. Both 
the supernatant and pellet were stored at −80 °C prior to 
analysis.
Assessment of urinary CXCL1, creatinine and protein levels
The level of human CXCL1 (Cat# DGR00 R & D Systems 
Inc., Minneapolis, USA) was monitored in urine samples 
using enzyme-linked immunosorbent assays (ELISA). 
Readers of this assay were blinded as to disease status. 
The assays were conducted according to the manufactur-
er’s instructions. Calibration curves were prepared using 
purified standards. Curve fitting was accomplished by 
either linear or four-parameter logistic regression follow-
ing manufacturer’s instructions.
The relatively constant production of creatinine, a non-
enzymatic metabolite of creatine, makes urinary cre-
atinine a useful tool for normalizing the levels of other 
molecules found in urine (Reid et al. 2012). The concen-
tration of urinary creatinine was measured using a com-
mercially available enzymatic assay (Cat# KGE005 R & 
D Systems Inc., Minneapolis, MN, USA) according to 
the manufacturer’s instruction. Briefly, urine superna-
tants were treated with alkaline picrate solution, which 
yields an orange-red color when in the presence of cre-
atinine. Intensity of the color at 490 nm corresponds to 
the concentration of creatinine in the sample. Creatinine 
concentrations of unknown samples were calculated by 
comparison to a standard curve.
Data analysis
The association between CXCL1 and BCa was tested 
using Wilcoxon rank sum test. Nonparametric receiver 
operating characteristic (ROC) curves were generated 
in which the value for sensitivity is plotted against false-
positive rate (1-specificity). Areas under ROC curves were 
estimated and compared by Chi-square test. We defined 
a diagnostic test (positive vs. negative) for BCa using a 
cutoff threshold for CXCL1. The optimal cutoff (Youden 
index) was selected to maximize the sum of the sensitivity 
and specificity (Edgar et al. 2002). The overall accuracy of 
a biomarker to predict BCa is defined as the percentage of 
correctly predicted BCa or non-BCa. To assess the inde-
pendent association of CXCL1 to BCa, logistic regres-
sion analysis was performed with BCa status (yes vs. no) 
as the dependent variable and with gender, age, race, 
tobacco exposure and CXCL1 concentrations as explana-
tory variables. Statistical significance in this study was set 
at p < 0.05 and all reported p values were two-sided. All 
analyses were performed with SAS software version 9.4.
Results
The cohort of 86 subjects consisted of 43 subjects with 
active BCa and 43 control subjects. Demographic, clini-
cal, and pathologic characteristics of both groups are 
illustrated in Table  1. In the cancer cohort, VUC had a 
sensitivity of only 51 %. Due to the unavoidable variability 
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of voided urine with respect to total volume and time 
within the bladder, CXCL1 was normalized to urinary 
creatinine. Mean urinary concentrations of CXCL1 were 
significantly higher in subjects with BCa compared to 
subjects without BCa (179.8 ± 371.7 pg/mg of creatinine 
vs. 28.2 ± 71.9 pg/mg, respectively p = 0.0009). Though 
the mean urinary CXCL1 concentrations were elevated 
in high grade vs. low-grade disease (229.5  ±  430.2 
vs. 69.3  ±  112.0  pg/mg, respectively p  =  0.9170) and 
high-stage vs. low-stage disease (253.1  ±  412.6 vs. 
133.2 ± 345.9 pg/mg, respectively p = 0.2862), the results 
were not significant. ELISA data are depicted in Fig. 1. 
The ability of CXCL1 to predict the presence of BCa in 
voided urines was analyzed using nonparametric ROC 
analyses and the area under the ROC curve (AUROC), 
according to National Cancer Institute guidelines (Pepe 
et al. 2008). We determined the Youden Index cutoff val-
ues, which maximize the sum of sensitivity and specific-
ity. Using the Youden Index cutoff value, urinary CXCL1 
provided a sensitivity of 55.81  %, specificity of 83.72  %, 
positive predictive value of 77.42  %, negative predic-
tive value of 65.46 % with an overall accuracy of 69.77 % 
(AUROC: 0.7015, 95 % CI 0.5903–0.8126, Fig. 2).
Discussion
Cancer of the urinary bladder is among the five most 
common malignancies worldwide (Siegel et  al. 2014). 
At presentation, more than 80  % of bladder tumors are 
NMIBC (Ta, T1 or Tis), which harbor a 5-year survival 
rate of approximately 94 %, however, approximately 70 % 
of patients with these lesions develop tumor recurrence 
within 2 years of initial diagnosis (Brausi et al. 2011). The 
recurrence phenomenon of NMIBC makes it one of the 
Table 1 Demographic, clinicopathologic characteristics 





Median age (range, y) 63 (34–81) 67 (20–89)
Male:female ratio 36:7 36:7
Race
 White 27 (63) 41 (95)
 African American 2 (5) 1 (2)
 Other 14 (33) 1 (2)
Tobacco use 16 (37) 32 (74)
Suspicious/positive cytology 0 (0) 22 (51)
Median follow-up (range, months) 3.5 (1–49) 6 (1–43)
Clinical stage
 Tis n/a 0 (0)
 Ta n/a 14 (33)
 T1 n/a 11 (26)
 T2 n/a 16 (37)
 T3/4 n/a 2 (4)
Grade
 Low n/a 31 (72)

























































































Fig. 1 Comparison of urine concentrations of CXCL1 between a the 
cancer and non-cancer groups, b low-grade and high-grade BCa and 
c low stage (NMIBC) and high stage BCa (MIBC). Data are normalized 
to urinary creatinine. Horizontal lines depict median levels. Signifi-
cance (p < 0.05) was assessed by the Wilcoxon rank sum test
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most prevalent cancers world-wide (in America it is sec-
ond only to colorectal cancer) and is, therefore, a great 
burden to our healthcare system (Surveillance, Epidemi-
ology, and End Results Program 2013). Then at presen-
tation, approximately 20 % of bladder tumors are MIBC 
(T2-T4), which carries at best a 50  % 5-year survival 
rate, or metastatic, which portends a dismal 5-year sur-
vival rate <20 % (Witjes et al. 2014). Thus, we continue to 
search for means to enable early detection of BCa, ideally 
through non-invasive urine-based analysis.
In this current report, we describe the analysis of uri-
nary CXCL1 in a cohort of 86 subjects using a com-
mercial ELISA assay. Urinary protein concentration of 
CXCL1 was significantly associated with BCa compared 
to controls (179.8 ± 371.7 vs. 28.2 ± 71.9 pg/mg, respec-
tively p =  0.0009). However, its diagnostic capability as 
a standalone biomarker, sensitivity of 55.81 %, specificity 
of 83.72 %, positive predictive value of 77.42 %, negative 
predictive value of 65.46  % with an overall accuracy of 
69.77 %, was less than ideal.
CXCL1 has not been widely reported on in the BCa 
literature, although a related chemokine, interleukin 8 
(IL8), has been extensively studied (Reis et al. 2012; Lei-
bovici et  al. 2005; Escudero-Lourdes et  al. 2012; Black 
and Dinney 2007). Oncomine analysis of datasets posted 
by Sanchez-Carbayo et  al. (2002), Dyrskjot et  al. (2003), 
Lee et  al. (2010) demonstrated significant elevation of 
CXCL1 mRNA levels in human BCa tissues, specifically 
higher CXCL1 mRNA levels in MIBC compared to 
NMIBC. The data stand to further substantiate our previ-
ous reported findings that CXCL1 protein was noted to 
be significantly increased in high-stage compared to low-
stage and high-grade compared to low-grade BCa tissues 
(Miyake et al. 2013). In this study, there were no signifi-
cant differences in urinary CXCL1 levels between high-
stage and low-stage, and high-grade and low-grade. This 
may be due to different samples, tumor and urine. Since 
previous studies employed BCa tissues, it is considered 
that CXCL1 levels directly reflect BCa stage and grade. 
However, we analyzed CXCL1 levels in voided urine. Pre-
vious studies have shown that urinary protein analysis 
is a tool for detecting genitourinary diseases including 
prostate cancer, renal cell carcinoma and BCa (Adachi 
et al. 2006), meaning that urinary CXCL1 levels might be 
affected by other factors in addition to BCa.
Unfortunately, CXCL1 expression is not unique to BCa. 
Several benign inflammatory bladder disorders are noted 
to express and secrete higher levels of CXCL1 compared 
to normal bladder tissue (Tyagi et  al. 2010; Zhao et  al. 
2015). Such benign conditions can then adversely affect 
the specificity of CXCL1, further limiting its role as a 
single diagnostic biomarker. However, since CXCL1 is 
overexpressed and secreted in variety of disease states, 
thought should be given to its potential as a therapeutic 
target.
We recognize that our study has several limitations. 
First, our analyses were performed on processed, banked 
urines. These urines were centrifuged and separated 
into cellular pellet and supernatant prior to storage at 
−80  °C. It is feasible that freshly voided urine samples 
may provide different results, and it is fresh urine that 
would be the material used for point-of-care assays. Sec-
ond, it is uncertain how the protein composition of the 
urine supernatant may change during frozen storage. 
The number of freeze–thaw cycles was kept to 1–2 by 
dividing the urine supernatant into multiple small ali-
quots. Next, we are a tertiary care facility that is prefer-
entially referred high grade, higher stage disease, which 
is reflected in our cohort. Lastly, we believe that a more 
robust diagnostic approach would encompass a diag-
nostic signature composed of numerous biomarkers, as 
we previously published (Chen et al. 2014; Rosser et al. 
2013, 2014).
Conclusions
We have confirmed that urinary levels of CXCL1 were 
elevated in a population of 43 BCa patients relative to 43 
control subjects. Though CXCL1 may lack robustness as 
a sole diagnostic biomarker, it may be a viable therapeutic 
target in the future.
Fig. 2 Receiver operating characteristic (ROC) curves for urinary 
CXCL1. Based on the area under the ROC curve (AUROC), Youden 
Index cutoff values that maximized the sum of sensitivity and speci-
ficity were determined for each biomarker
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